<DOC>
	<DOCNO>NCT00844883</DOCNO>
	<brief_summary>This study combine two therapy treat patient unresectable hepatocellular carcinoma ; sorafenib , drug elute bead deliver intra-arterially . The purpose study establish safety effectiveness combination therapy . The investigator hypothesize combination two therapy result great toxicity patient expect either therapy give alone .</brief_summary>
	<brief_title>Study Sorafenib Transarterial Chemoembolization ( TACE ) Treat Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . Unresectable hepatocellular carcinoma patient liverpredominant disease describe section 5.1 , patient hepatocellular carcinoma refuse surgery . No 30 % cohort macrovascular invasion and/or asymptomatic extrahepatic disease . Multifocal HCC acceptable , diffuse HCC . 2 . Age &gt; 18 year old 3 . ECOG performance status 01 4 . Childs class A B ( 7 ) ( see Table 5.0 ) 5 . Adequate endorgan function manifest : Absolute neutrophil count &gt; 1500/mm3 platelet &gt; 50,000/mm3 Creatinine ≤ 2.0 AST ALT &lt; 5 x ULN Total bilirubin ≤ 3 Albumin &gt; 2.0 INR &lt; 2.0 Leukocyte count &gt; 3000 cells/mm3 6 . Amylase lipase ≤ 1.5 upper limit normal 7 . Patients receive previous hepatic surgery , RFA , PEI , cryoablation eligible target lesion ( ) treat local therapy complete &gt; 6 week prior entry . 8 . Left ventricular ejection fraction ≥ 45 % 9 . Patients asymptomatic HIV infection eligible 10 . Willingness male female subject , surgically sterile post menopausal , use reliable method birth control duration study 30 day last dose study medication . 11 . Patient must sign informed consent prior registration study . 12 . Resolution acute toxic effect prior local treatment CTC adverse event Grade 1 0 . 13 . At least one tumor lesion accurately measure least one dimension accord RECIST . The lesion previously treat local therapy ( surgery , radiation therapy , RFA , PEI , cryoablation ) unless show progression interim . 1 . Patients unable swallow oral medication 2 . Prior embolization , systemic radiation therapy HCC ( liver ) 3 . Tumor burden liver exceed 70 % . 4 . Complete occlusion entire portal venous system 5 . Ascites refractory diuretic therapy ( minimal trace image acceptable ) 6 . Previous concurrent cancer distinct primary site histology HCC , except cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumor ( Ta , Tis , T1 ) . Any cancer curatively treat &gt; 3 year prior permit . 7 . Patients clinically significant gastrointestinal bleeding within 30 day prior study entry 8 . History bleed within past 4 week ( unless deem PI clinically insignificant , ex. , brief episode epistaxis ) 9 . Any contraindication doxorubicin administration 10 . Evidence severe uncontrolled systemic disease , 11 . Congestive cardiac failure &gt; NYHA class 2 , MI within 6 month , active coronary artery disease , cardiac arrhythmia require antiarrhythmic therapy beta blocker digoxin , unstable angina , laboratory find view investigator make undesirable patient participate trial 12 . Any prior history hypertensive crisis hypertensive encephalopathy 13 . History stroke transient ischemic attack within 6 month prior study enrollment 14 . Inadequately control hypertension ( define systolic blood pressure 150/100 mmHg antihypertensive medication ) ( patient treat hypertension eligible ) 15 . Significant vascular disease ( e.g. , aortic aneurysm , aortic dissection , peripheral vascular disease ) 16 . History organ allograft 17 . Presence grade &gt; 2 hepatic encephalopathy ( see Appendix D ) 18 . Current , recent ( within 4 week first infusion study ) , plan participation additional experimental drug 19 . Evidence bleed diathesis coagulopathy warfarin . Note : If patient coumadin period 1 month stable , may accept protocol . 20 . Presence clinically evident central nervous system brain metastases 21 . Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 1 , anticipation need major surgical procedure course study 22 . Vascular anatomy precludes catheter placement injection LC Bead microspheres 23 . Presence collateral vessel pathway potentially endanger normal territory embolization 24 . Pregnant ( positive pregnancy test ) lactate 25 . Inability comply study and/or followup procedure 26 . Life expectancy le 12 week 27 . Child B8 , B9 C 28 . ECOG ≥ 2 29 . Patients concomitant HIV infection AIDSrelated serious acute chronic illness 30 . Presence portosystemic shunt 31 . Severe atheromatosis 32 . Substance abuse , medical , psychological social condition may interfere patient 's participation study evaluation study result 33 . Active clinically serious infection ( &gt; grade 2 ) 34 . Patients receive therapy hepatitis A , B , C. 35 . Patients obvious and/or symptomatic extrahepatic disease . Findings uncertain significance , lung lesion less 10 mm diameter enlarge periportal lymph node exclude patient , however , finding highly suspicious metastatic HCC exclude patient study . 36 . Any contraindication arterial procedure impair clot test ( platelet count &lt; 50.000/mm3 prothrombin activity &lt; 50 percent ) 37 . Any contraindication systemic chemotherapy administration ( serum bilirubin &gt; 3mg/dL , leukocyte count &lt; 3.000 cells/mm3 ) 38 . Any contraindication sorafenib administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>primary liver cancer</keyword>
	<keyword>sorafenib</keyword>
	<keyword>Nexavar</keyword>
	<keyword>doxorubicin</keyword>
	<keyword>drug elute bead</keyword>
	<keyword>transarterial chemoembolization</keyword>
</DOC>